4592 Share Price Performance
JP¥0
-2119.00 (-100.00%)
Price JP¥0
Fair ValueJP¥1,660.00
Share Pricen/a
Narrative Update • Jun 26
SanBio Company Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
4592 Community Narratives
AN
Fair Value
·Fair Value JP¥1.66k 38.4% undervalued intrinsic discount
Regenerative Medicine Tailwinds Will Support Long Term Brain Disease Treatment Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value JP¥2.9k 64.7% undervalued intrinsic discount
Brain Regeneration Platform Will Transform Chronic Injury Treatment And Open Multiple Future Indications
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regenerative Medicine Tailwinds Will Support Long Term Brain Disease Treatment Potential
SanBio is racing to bring a cell-based treatment for traumatic brain injury to market in Japan, helped by a supportive local approval system and early manufacturing scale-up. The big question is whether approvals, trials, and doctor adoption arrive on time before higher spending and possible share dilution start to weigh on the story.Read more
AN
JP¥1.66k
38.4% undervalued intrinsic discount
Fair Value
Profit Margin
4.52%
Future PE
251x
Price in 2029
JP¥0
Brain Regeneration Platform Will Transform Chronic Injury Treatment And Open Multiple Future Indications
Catalysts About SanBio SanBio is a regenerative medicine company focused on cell therapies for brain diseases such as traumatic brain injury and ischemic stroke. What are the underlying business or industry changes driving this perspective?Read more
AN
JP¥2.9k
64.7% undervalued intrinsic discount
Fair Value
Profit Margin
7.86%
Future PE
589.96x
Price in 2029
JP¥0
Trending Discussion
Recently Updated Narratives
AN
4592: Conditional Approval And Reimbursement Will Support Future Regenerative Therapy Upside
Fair Value: JP¥1.66k 38.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Brain Regeneration Platform Will Transform Chronic Injury Treatment And Open Multiple Future Indications
Fair Value: JP¥2.9k 64.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
SanBio Company Limited Key Details
About 4592
- Founded
- 2001
- Employees
- 33
- CEO
- WebsiteView website
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company’s research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
